New Haven Pharmaceuticals develops prescription pharmaceuticals that utilize drugs or GRAS active pharmaceutical ingredients.
New Haven Pharmaceuticals (NHP) is a specialty pharmaceuticals company developing proprietary prescription pharmaceuticals that utilize currently marketed drugs or generally recognized as safe (GRAS) active pharmaceutical ingredients (APIs) for use in therapeutic applications that represent significant market opportunities. The company's novel product pipeline employs proprietary, oral, controlled-release technologies, as well as intellectual property licensed from Yale University, which will enable optimal dosing, safety, efficacy and patient convenience.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 17, 2016 | Debt Financing | $602.22K | 1 | — | — | Detail |
Oct 7, 2015 | Debt Financing | $6.30M | 1 | — | — | Detail |
Oct 23, 2014 | Series B | $11.78M | 1 | — | — | Detail |
Dec 31, 2013 | Debt Financing | — | 1 | — | — | Detail |
Oct 29, 2012 | Series A | $6.49M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Advantage Capital | — | Debt Financing |
Horizon Technology Finance | — | Debt Financing |
EJ Funds | — | Series B |